<DOC>
	<DOC>NCT00332202</DOC>
	<brief_summary>This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily. This is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.</brief_summary>
	<brief_title>PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>Clinical diagnosis of diffuse large B cell lymphoma Recently completed RCHOP therapy and achieved remission IPI score 3,4,5 At least 18 years of age Agree to study followup schedule Have received therapy other than RCHOP for lymphoma Serious medical condition such as infection,second cancer,heart disease Received radiation to more than one lesion Unable to swallow tablets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>